106 results about "Systemic inflammation" patented technology

The invention relates to a plant lactobacillus with effects of dispelling effects of alcohol, protecting the liver and restoring consciousness and application of the plant lactobacillus. The plant lactobacillus is a plant lactobacillus BGI-J9 strain, and the preservation number of the plant lactobacillus is CCTCC NO: M 20242630. The invention further discloses a preparation method of the plant lactobacillus with the effects of dispelling effects of alcohol, protecting the liver and restoring consciousness and application of the plant lactobacillus with the effects of dispelling effects of alcohol, protecting the liver and restoring consciousness. The strain has excellent tolerance to gastric acid, intestinal juice and cholate in a gastrointestinal tract system, can survive in the gastrointestinal tract, and provides a basis for continuously playing a probiotic effect; the compound has excellent inhibition capability on common intestinal pathogens; free radicals can be removed, and oxidative damage to the body is reduced; good alcohol metabolism enzyme synthesis capability and alcohol metabolism promoting potential are realized; the strain also has an excellent improvement effect on alcohol-damaged mice, specifically, the metabolism of ethanol and acetaldehyde in a body is accelerated, the occurrence time of drunkenness is obviously delayed, and the sobering time is shortened; intestinal injury and systemic inflammation caused by alcohol are improved; liver oxidative stress caused by alcohol is improved, and the occurrence and development process of alcoholic fatty liver is delayed; and cognitive function impairment caused by alcohol is improved.

The invention discloses chiral ionizable lipid nanoparticles and a preparation method thereof, and belongs to the technical field of biomedical materials. The chiral ionizable lipid nanoparticle comprises chiral amino acid derived lipid, ionizable lipid, auxiliary lipid, cholesterol, a phospholipid polyethylene glycol derivative and an RNA (Ribonucleic Acid) drug, the preparation method comprises the following steps: dissolving chiral amino acid derived lipid in methanol, respectively dissolving ionizable lipid, auxiliary lipid, cholesterol and phospholipid polyethylene glycol derivative in ethanol, and mixing to obtain a total lipid organic phase; dissolving an RNA drug in DEPC water to obtain an RNA aqueous solution, and mixing the RNA aqueous solution with an acidic buffer solution to obtain an RNA aqueous phase; quickly mixing the total lipid organic phase and the RNA water phase, and standing and incubating; adding the mixed solution into a 3500 Da dialysis bag, taking 1 * phosphate buffer solution (PBS, pH = 7.4) as an external water phase, and dialyzing to obtain the chiral ionizable lipid nanoparticles. The lipid nanoparticles provided by the invention can enhance the RNA uptake efficiency, and have good application prospects in the treatment of systemic inflammation and other diseases.

The invention belongs to the technical field of biological medicines, and particularly discloses application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. According to the application of the (E)-BCI hydrochloride in preparation of the medicine for treating sepsis, by inhibiting the activity of bispecific phosphatase 6, a mitogen activated protein kinase signal channel is regulated and controlled, and the expression level of inflammatory factors IL-1beta and TNF-alpha is reduced. The invention discloses application of (E)-BCI hydrochloride in preparation of drugs for treating sepsis, BCI enters from a new target for regulating inflammation and immune balance through a targeted DUSP6 / MAPK signal channel, a non-antibiotic-dependent drug is provided for treatment of sepsis, and the (E)-BCI hydrochloride is especially suitable for systemic inflammatory response syndromes caused by infection, operations, wounds and other inducements, and has a wide application prospect. Wide clinical application prospects are realized.

The invention discloses a bone defect repair material suitability prediction method based on deep learning, and the method comprises the steps: carrying out the overlapping and uniform partitioning of a bone defect region and a host bone region in three-dimensional CT image data, carrying out the position coding and feature extraction of a plurality of sub-blocks through a three-dimensional visual Transform model of multi-scale position coding, and obtaining the anatomical and functional features; calculating a bone metabolism activity score and a systemic inflammation score based on blood detection data, and then constructing pathophysiological features; performing multi-round interaction on the anatomical and functional features, the pathophysiological features, the parameter data and the multidirectional multi-head cross attention layer, in each round, selecting one modal feature as a query vector, and selecting any modal feature in the rest modal features as a key vector and a value vector; and fusing the interaction features of each round, and determining the suitability score and the risk level of the bone repair material by combining the attention weight and the bone metabolism activity score in the multidirectional multi-head cross attention layer.

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. According to the application of lanthanum carbonate in preparation of the medicine for treating hepatic encephalopathy, the medicine comprises lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate, the medicine is ground and then mixed with food to prepare a medicine mixture, and the medicine mixture is prepared into the medicine for treating hepatic encephalopathy. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%. According to the application, the blood ammonia is reduced based on the glutaminase, the hepatic encephalopathy is reversed by reducing the blood ammonia and systemic inflammation, and the liver function is recovered by regulating the inflammation, so that the hepatic encephalopathy is favorably cured, a good treatment effect is shown, and a new candidate medicine is provided for clinically treating the hepatic encephalopathy.

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected by S. pneumoniae and protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention discloses a method for improving the quality of ganoderma lucidum mushroom residues through synergistic fermentation of bacteria and enzymes and application of the method. According to the method disclosed by the invention, cellulase, beta-galactosidase and xylanase with proper concentrations and lactobacillus plantarum, bacillus subtilis and saccharomyces cerevisiae with proper proportions are adopted, and enzymes and bacteria are mutually cooperated, so that the characteristics of the raw materials are well balanced, the finally prepared ganoderma lucidum mushroom bran is high in protein content and low in fiber content, and the nutritional value of a feed is improved; the total amount of amino acids and essential amino acids are remarkably increased, and the feed protein quality can be improved; the rumen dry matter digestibility and energy metabolites are remarkably improved, and ruminant absorption and utilization are facilitated; the ganoderma lucidum mushroom bran fermented feed is added into the daily ration, so that the daily gain, the carcass rate and the dressing percentage of fed animals can be remarkably improved, the levels of serum GLU, TG, ALT and AST are reduced, the expression of key inflammatory cytokines (IL-1beta and IL-6) is inhibited, and the ganoderma lucidum mushroom bran fermented feed has the comprehensive effects of regulating glycolipid metabolism and relieving liver load and systemic inflammation, so that the immune function of animal bodies is improved.

This disclosure presents systems and methods for baroreflex activation therapy (BAT) to regulate inflammation by modulating autonomic nervous system activity. Electrical stimulation is delivered to one or more baroreceptors, and real-time physiological signals are monitored, including inflammatory biomarkers (e.g., TNF-α, IFN-γ, IL-1, IL-6, IL-12, CRP) and autonomic parameters such as heart rate variability (HRV). A closed-loop feedback module analyzes biomarker fluctuations and autonomic balance changes and dynamically modifies stimulation parameters, including amplitude, pulse width, frequency, and duty cycle, to suppress systemic inflammation and restore autonomic balance. In certain embodiments, multi-channel stimulation architectures and AI-driven algorithms or machine learning models analyze biomarker trends and historical patient response patterns to optimize therapy. The disclosed BAT systems and methods may be used to treat inflammatory diseases, autoimmune disorders, cancer progression, chronic inflammatory pain conditions, arrhythmias associated with inflammation, and metabolic dysfunction.

The application provides a marker for diagnosing systemic inflammation and application, the marker comprising ADGRE3 mRNA or ADGRE3 protein, or ADGRE3 mRNA fragment, ADGRE3 protein fragment, and the marker content in samples of systemic inflammation patients and healthy people has significant difference, and the marker diagnosis has high sensitivity and specificity in clinical verification, therefore, by detecting the ADGRE3 mRNA transcription level or the ADGRE3 protein expression level in the individual sample, systemic inflammation can be accurately diagnosed.Compared with existing inflammation markers, ADGRE3 mRNA and ADGRE3 protein have higher sensitivity and specificity in diagnosing systemic inflammation.

Disclosed are methods of treating sepsis in an individual in need thereof via administration of a therapeutically effective amount of a humanin protein, or an analog thereof, to the individual. In one aspect, the methods may comprise administration of the humanin analog colivelin for reducing lung, liver and kidney injury and systemic inflammation after an infection.

The application relates to the technical field of medicines, and discloses application of gymnemon and a medicine thereof.According to the application, the gymnemon can be used for preparing medicines related to cardiovascular diseases, including medicines for improving heart failure, inhibiting myocardial hypertrophy, improving vascular endothelial function and reducing blood pressure, and further used for preparing medicines for reducing expressions of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 and / or increasing serum NO level; the gymnemon can also be used for preparing medicines for regulating abnormal lipid metabolism, including medicines for reducing triglyceride and total cholesterol level; the gymnemon can also be used for preparing medicines for relieving liver injury, including medicines for reducing glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase level; and the gymnemon can also be used for preparing medicines for improving systemic inflammation and / or platelet and thrombin dysfunction.

The present invention relates to the field of diagnostics. Specifically, the present invention relates to a method for assessing systemic inflammation in a subject exhibiting symptoms of systemic inflammation, the method comprising: a) determining the amount of biomarkers from a set of biomarkers selected from the group consisting of: i) a first set of biomarkers comprising POMK, NEK6, KCNA5, LARGE2, ZNF425, NACA2, CFAP57, SPINT1, ZNF492 and S100A6, ii) a second set of biomarkers comprising a first set of biomarkers comprising POMK, NEK6, KCNA5, LARGE2, ZNF425, NACA2, CFAP57, SPINT1, ZNF492 and S100A6, and iii) a third set of biomarkers comprising POMK, NEK6, KCNA5, LARGE2, the present invention relates to a method for identifying systemic inflammation in a subject comprising: a) a first set of biomarkers comprising: NEK6, SRPK3, TNFSF8, S100A6, NMUR1, DHFR, HIST1H4D, ZDHHC4, TRAF3 and SGMS1, or iii) a third set of biomarkers comprising: C9orf135, ZNF425, ACOT4, SPDYA, DAPP1, LY86, ZPBP2, RPL3L, UPK1B and APBB3, b) comparing the determined amounts of biomarkers from the set of biomarkers to a reference, and c) assessing systemic inflammation in the subject. In addition, the present invention generally relates to the use of the amount of said biomarker in a sample of a subject exhibiting symptoms of systemic inflammation for assessing systemic inflammation. In addition, a device and a kit for assessing systemic inflammation are contemplated.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

This invention provides pharmaceutical compositions for inhibiting inflammation and their applications. The invention reveals that the combined use of hyaluronic acid synthesis inhibitors and ascorbate palmitate or their analogues can synergistically inhibit inflammation, significantly improving the therapeutic effect; the inflammation may include systemic inflammation and SARS-CoV-2 infection-related inflammation, including pneumonia. This invention also reveals a novel coronavirus inflammation model obtained by stimulating cells with specially isolated polynucleotides derived from the novel coronavirus genome. The model exhibits a typical inflammatory phenotype, is stable and controllable, and is intuitive and easy to observe.

This invention belongs to the field of biomedical technology, specifically relating to the application of a functional lipid in the preparation of drugs for treating systemic lupus erythematosus (SLE). Specifically, the functional lipid MLnM exhibits significant therapeutic effects in a pristane-induced SLE mouse model, effectively alleviating SLE-related clinical symptoms, improving intestinal barrier function, reducing oxidative stress levels, regulating the balance of inflammatory cytokine secretion, and reducing systemic inflammatory responses by inhibiting the expression of immune cell migration-related genes. The discovery of MLnM provides a new direction for the treatment of SLE and other autoimmune diseases.

The invention belongs to the technical field of animal models, and relates to a construction method of a febrile infection associated epileptic syndrome (FIRES) animal model. The method comprises the following steps: firstly, injecting lipopolysaccharide (LPS) into the abdominal cavity of a normal mouse to induce systemic inflammatory reaction, and simulating a fever process in combination with thermal exposure; 4-aminopyridine (4-AP) is injected into the brain of the mouse 24 hours after the injection of lipopolysaccharide (LPS) is finished to induce the occurrence of the epilepsy syndrome related to the hot infection of the normal mouse, and the model of the epilepsy syndrome related to the hot infection of the mouse is constructed. Typical characteristics of FIRES are successfully simulated: precursory fever (2 weeks to 24 hours before attack), an electroencephalogram (EEG) shows beta-delta complex waves and rhythmic sharp waves of extreme delta brushing, and a multi-drug-resistant epileptic state. The invention provides the novel construction method of the mouse fever infection related epileptic syndrome model, the model characteristics are typical, the modeling success rate is high, and the modeling period is short. Wide application prospects are realized.

The invention provides application of resolvin D1 in periodontitis systemic complications, and belongs to the technical field of biological medicine. The new function of the RvD1 is found, that is, the RvD1 has the effects of relieving and / or treating periodontitis systemic complications and promoting systemic inflammation regression. As an endogenous molecule, the RvD1 has fewer side effects and can be better tolerated by a human body. The RvD1 can directly act on an inflammation regulation process, promote inflammation regression and regulate the balance of host immune response, is helpful for controlling the development of periodontitis and systemic complications and reducing repeated attack, and provides a safer, more comprehensive and more effective treatment scheme for periodontitis and systemic complications.

The application discloses a kind of bone defect repair material adaptability prediction methods based on deep learning, the bone defect region and host bone region in three-dimensional CT image data are overlapped and evenly divided, and the three-dimensional visual Transformer model of multi-scale position coding is used to carry out position coding and feature extraction to multiple sub-blocks, to obtain anatomical and functional characteristics;Pathophysiological characteristics are constructed after calculating bone metabolic activity score and systemic inflammation score based on blood test data;Anatomical and functional characteristics, pathophysiological characteristics, parameter data and multi-direction multi-head cross attention layer are interacted in multiple rounds, in each round, select a modal feature as a query vector, select any modal feature in the remaining modal feature as a key vector and a value vector;The interactive features of each round are fused, and the adaptability score and risk level of bone repair material are determined by combining the attention weight in the multi-direction multi-head cross attention layer and the bone metabolic activity score.

The present disclosure relates to a methods, compositions and kits for the diagnosis and prognosis of sepsis and / or associated conditions, as well as tailoring personalized treatment regimens based on the balance between systemic inflammation and resistance state of subjects in need. The disclosed methods involve calculating the resistance (R) level and the systemic inflammation (SI) level of a subject to determine a R / SI balance score that enables classification of the subject.

A method of treating or preventing cardiovascular disease which comprises administering a therapeutically effective amount of at least one n-3 DPA-derived resolvin and / or upregulating or increasing the biosynthesis or activity of at least one n-3 DPA-derived resolvin. n-3 DPA-derived resolvins are normally regulated diurnally in the body and are linked to activation of platelets and leucocytes and formation of platelet-leukocyte aggregates. Dysfunctional regulation of n-3 DPA-derived resolvins may lead to systemic inflammation because of excessive inflammation-inducing eicosanoids, especially in the early hours of the morning. Further, decreased 5-LOX / 15-LOX expression and increased systemic adenosine concentrations are found to be associated with reduced resolvin levels and increased risk of cardiovascular disease. n-3 DPA-derived resolvins are administered to achieve maximum absorption in the early hours. Also disclosed are n-3 DPA-derived resolvins for use in the treatment or prevention of cardiovascular disease, and methods for measuring the levels of n-3 DPA-derived resolvins and / or the expression or activity of adenosine or 5-LOX / 15-LOX in biological samples obtained from a subject for assessing the subject's risk of cardiovascular disease.

Embodiments of the invention include the use of flavonoids to modulate inflammation of the CNS. Formulations and methods described herein can treat traumatic brain injuries (TBI) and Alzheimer's disease (AD) by reducing systematic inflammation and modulating immune dysregulation. The formulations and methods include antagonists that bind to receptors (CCR2 and GPR55) and a prostaglandin (PGE2). When administered therapeutically with 17-DHA and / or THEA, their combined activity can reduce systemic inflammation and post-trauma inflammation. In aspects, one or more of the compounds work synergistically with one another.

The invention is concerned with a fusion protein, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and / or lymphoproliferation.

The present invention belongs to the field of biomedicine and specifically discloses the use of a sesquiterpene lactone compound from Yemazhui in the preparation of a drug for treating polycystic ovary syndrome. The use of the sesquiterpene lactone compound from Yemazhui in the preparation of a drug for treating polycystic ovary syndrome disclosed in the invention has the following beneficial effects: 1. For the first time, the sesquiterpene lactone compound from Yemazhui was applied to a mouse model of polycystic ovary syndrome. Related experiments demonstrated that the sesquiterpene lactone compound from Yemazhui alleviated polycystic ovary syndrome symptoms and inhibited ovarian and systemic inflammation; 2. The sesquiterpene lactone compound from Yemazhui has been clinically used, has a single component, and is safe and reliable, facilitating clinical application and promotion.

Among various mRNA carrier systems, lipid nanoparticles (LNPs) stand out as the most clinically advanced. While current clinical trials of mRNA / LNP therapeutics mainly address liver diseases, the potential of mRNA therapy extends far beyond. To fully unlock the promises of mRNA therapy, there is an urgent need to develop safe and effective LNP systems that can target extrahepatic organs. Embodiments disclosed herein, are directed to novel sulfonium lipid nanoparticles (sLNPs) for systemic mRNA delivery to the lungs. sLNP effectively and specifically deliver mRNA to the lungs following intravenous administration in mice. No evidence of lung and systemic inflammation or toxicity in major organs was induced by sLNP. Our findings demonstrated that the newly developed lung-specific sLNP platform is both safe and efficacious and provides for the development of new mRNA-based therapies for the treatment of lung-associated diseases and conditions.

The invention discloses an application of bifidobacterium animalis subsp. Lactis SS9 in preparation of a product for preventing and treating stress obesity. The bifidobacterium animalis subsp. Lactis SS9 obtained by screening can remarkably relieve obesity induced by combination of chronic pressure and high-fat diet, and the obesity is represented by slowing down weight increase, reducing appetite, improving blood fat, up-regulating GLP-1 and insulin secretion and effectively relieving anxiety-like and depression-like behaviors. Researches find that the strain can regulate the hypothalamic-pituitary-adrenal axis activation level, improve secretion imbalance of hormones such as CRH, ACTH and CORT, restore expression of appetite regulation factors such as NPY / AgRP / POMC of hypothalamic and relieve emotional eating behaviors. In addition, the strain can also reduce the systemic inflammation level, recover the diversity of intestinal flora and improve the proportion of beneficial bacteria. The invention provides the probiotics with multiple effects of regulating emotion, controlling body weight and improving metabolic disorder, and a new strategy is provided for preventing and treating stress-related obesity.

This article provides compositions comprising an EV, such as an exogenous form, of a STING agonist, and methods for producing said compositions. This article also provides a method for modulating an immune response by administering a therapeutic amount of an EV, such as an exogenous form, of a STING agonist. The immune response may be an IENβ response or activation of myeloid dendritic cells (mDCs). This article further provides a method for modulating an immune response by administering an exogenous form of a STING agonist without inducing systemic inflammation.

The present invention provides the use of a pharmaceutical composition in the preparation of a medicament for treating diseases associated with high permeability of the blood-brain barrier and intestinal barrier. The pharmaceutical composition contains pharmaceutically acceptable β-hydroxybutyrate and vitamin D as active ingredients. In classical systemic inflammations of nerves, intestines, etc. induced by bacterial endotoxin lipopolysaccharide (LPS), the pharmaceutical composition of the present invention can well reduce the high permeability of the blood-brain barrier and intestinal barrier, and play a role in treating central nervous system inflammation, nerve damage, behavioral abnormalities, etc.